Skip to main content
Equibles
EDIT logo

EDIT · Editas Medicine, Inc.

Track EDIT — free

Use EDIT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research EDIT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.60 +0.08 (+3.17%)
Russell 2000 member Rebalance outlook locked
Market Cap
$396.24M
Shares
153.58M
Volume · Oct 2 2.16M Avg daily vol (3M) 2.51M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.52 Open$2.61 Day$2.52–2.62 52W close$1.67–4.15 Avg vol 30d3.0M Short int30.0M · 19.5% float · 15.7d Short vol72% Last earningsMay 5, 2026 DataJan 2020–Oct 2026 Filing10-Q · Aug 5

Up next

Latest filing: 10-Q
filed Aug 5, 2026
Q2 2024 earnings call transcript
call held Aug 7, 2024

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$47.01M
Trailing 12 months
Net income (TTM)
−$73.95M
Trailing 12 months
Revenue growth YoY
+232.3%
Year over year
Operating margin
-161.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-30.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$155.91M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+41.3%
Year over year · more shares
Price change (1Y)
-29.0%
Trailing year
Short interest
19.5%
Latest settlement · 15.7 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 16.4 · calm Equity put/call 0.57
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −4%
below
Price vs 50-day avg −11%
below
RSI (14) 40
neutral
MACD trend Negative
52-week position 34%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return −18%
trailing
6-month return −14%
trailing
YTD return +23%
this year
Relative strength −27%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $3 › 200d $3 — 50d above 200d
Institutional flow Accumulating
+4% holders QoQ · +36 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
19.51% of float · ▼ -0.9% MoM · 15.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
218 holders — mid 3-yr range
Squeeze score 68
elevated · 0–100
Fundamentals
Strong
Revenue growth +133%
Y/Y
EPS growth +38%
Y/Y
Free cash flow $-165.8M
Balance sheet $88.0M
net cash
Quant / Vol
risk profile
Very High
Volatility 83%
annualized · 1-yr
Max drawdown −60%
past year
ATR 7.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 5 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−4% Neutral
Price vs 50-day avg
−11% Bearish
RSI (14)
40 Neutral
MACD trend
Negative Bearish
52-week position
34% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $3 › 200d $3 — 50d above 200d
Institutional flow Accumulating
+4% holders QoQ · +36 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
19.51% of float · ▼ -0.9% MoM · 15.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
218 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2 Now $3 · 34% Range high $4
vs 200-day avg -4% vs 50-day avg -11%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
EDIT
Editas Medicine, Inc.
this stock
$396.24M +22.9% +132.6% — 19.5%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +11.8% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -4.8% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +540.7% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
218
% held
78.7%
Net QoQ
+68.4M sh
Top holder
TCG Crossover Management,…
Held Float
View
Held by Funds
Fund positions
152
View
Short & Settlement
Short Interest Falling
Shares short
30.0M
Days to cover
15.7d
Change
-268.0K sh
View
Short Volume
Short vol %
72%
As of
Oct 2, 2026
Short Total
View
Fails to Deliver
FTD shares
57.8K
Value
$160.0K
As of
Sep 10, 2026
View
Off-Exchange
Off-exchange %
46.4%
Week of
Aug 24, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Daniel Goldman
Amount
$1.0K–$15.0K
Traded
Apr 10, 2023
View
Financials
Financials
Revenue (FY)
$40.5M
Net income (FY)
$-160.1M
EPS diluted
$-1.80
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 5, 2026
This year
16
View
Proposed Sales
Value
$2.3K
Shares
700
Filed
Aug 31, 2026
View
Earnings & Events
Webcasts
Last webcast
Jun 4, 2026
View

Performance

5D 20D 120D MTD YTD
EDIT -8.4% -18.2% -14.3% -2.0% +22.9%
SPY -0.4% -0.2% +12.4% +0.2% +12.0%
vs SPY -7.9% -18.0% -26.7% -2.1% +10.9%
Key facts CIK 1650664 CUSIP 28106W103 13F (30d) 4 filings 4 filers Visit website Investor relations